NSE: PFIZER | BSE: 500680

Mid-range Performer

Download real time

5042.30 21.10 (0.42%)

36.24% Gain from 52W Low

2,922 NSE+BSE Volume

NSE 17 Dec, 2025 10:53 AM (IST)

23,067.4

Market Cap

High in industry

Beta 1Year

Very Low volatility

Pfizer Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PFIZER, BSE:500680 Pfizer Ltd.

Pfizer Ltd.

10 Sep 2018

5042.30

0.42%

Pfizer

Hold: Pfizer Ltd.

Recommendation Target

Centrum Broking

Strong revenue growth: Pfizer's revenues are likely to grow faster than the market growth due to strong growth of its major brands. The growth was contributed by its major brands namely: Becosules, Ovral-L, Corex-Dx,Wysolone, Magnex, Neksium and Dolonex. We expect the company to report better revenue growth in FY19, led by the launch of a series of products as line extensions under the Corex brand name and the recent launch of Meronem and Neksium in India. The management indicated the launch of 3-4 new products per annum. Pfizer's 17 brands are in No.1 position in the...

Number of FII/FPI investors increased from 139 to 158 in Sep 2025 qtr.

Pfizer Ltd.

08 May 2018

5042.30

0.42%

Pfizer Ltd

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

FY18 revenues declined 3% YoY to | 1980 crore mainly due to GST impact, discontinuance of Corex cough syrup and divesture of certain brands. Q4FY18 revenues grew 15% YoY. Excluding...

Pfizer Ltd. is trading below its 50 day SMA of 5131.1

Pfizer Ltd.

19 Dec 2017

5042.30

0.42%

Pfizer Ltd

Buy: Pfizer Ltd.

ICICI Securities Limited

Pfizer Ltd. has an average target of 6100.00 from 1 broker.

Pfizer Ltd.

16 Nov 2017, 12:00AM

5042.30

0.42%

Pfizer

Buy: Pfizer Ltd.

Centrum Broking

Margin grew by 1,290bps YoY: Pfizer's EBIDTA margin for the quarter grew 1,290bps YoY to 29.3% from 16.4% due to overall decline in costs. Its material cost declined by 30bps YoY to 41.9% from 42.2% due to a profitable product mix. Personnel expenses declined by 60bps to 13.9% from 14.5%. Other expenses declined by 1,210bps to 14.9% from 27.0% as Q2FY17 had one-off expenses. The...

Pfizer Ltd. has an average target of 6100.00 from 1 broker.

Is Pfizer Ltd. worth buying?

213 Votes:

Buy 74.18%

Sell 14.55%

Hold 11.27%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf